[1] Dong H, Zhu G, Tamada K, et al. B7H1, a third member of the B7 family, costimulates Tcell proliferation and interleukin10 secretion[J]. Nat Med, 1999, 5(12): 1365-1369.
[2] Bigelow E, Bever KM, Xu H, et al. Immunohistochemical staining of B7H1 (PDL1) on paraffinembedded slides of pancreatic adenocarcinoma tissue[J]. J Vis Exp, 2013, 71: 4059.
[3] Hua D, Sun J, Mao Y, et al. B7H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma[J]. World J Gastroenterol, 2012, 18(9): 971978.
[4] Muller CY. Doctor, should I get this new ovarian cancer testOVA1?[J]. Obstet Gynecol, 2010, 116 (2 Pt 1): 246-247.
[5] Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer[J]. Proc Natl Acad Sci USA, 2007, 104(9): 33603365.
[6] Azuma T, Yao S, Zhu G, et al. B7H1 is a ubiquitous antiapoptotic receptor on cancer cells[J]. Blood, 2008, 111(7): 3635-3643.
[7] Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigenspecific CD8 T cells infiltrating the tumor express high levels of PD1 and are functionally impaired[J]. Blood, 2009, 114(8): 1537-1544.
[8] Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7H1 is associated with poor prognosis in renal cell carcinoma patients with longterm followup[J]. Cancer Res, 2006, 66(7): 3381-3385.
[9] Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death1 ligand1 and programmed death1 ligand2 expression in human esophageal cancer[J]. Clin Cancer Res, 2005, 11(8): 2947-2953.
[10] Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy[J]. Oncogene, 2007, 26(9): 1324-1337.
[11] Li P, Zhang ST, Yu ZL, et al. Effects of cyclooxygenase2 nonselective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells[J]. Dis Esophagus, 2009, 22(1): 2131.
[12] Anderson NS, Turner L, Livingston S, et al. Bcl2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation[J]. J Ovarian Res, 2009, 2: 16.
[13] Kang MH, Reynolds CP. Bcl2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy[J]. Clin Cancer Res, 2009, 15(4): 1126-1132.
[14] Zhang Z, Wu G, Gao J, et al. Inclusion complex of a Bcl2 inhibitor with cyclodextrin: characterization, cellular accumulation, and in vivo antitumor activity[J]. Mol Pharm, 2010, 7(4): 1348-1354.
[15] Avraam K, Pavlakis K, Papadimitriou C, et al. The prognostic and predictive value of ERCC1, p53, bcl2 and bax in epithelial ovarian cancer[J]. Eur J Gynaecol Oncol, 2011, 32(5): 516-520. |